Generating the Right Evidence at the Right Time: Principles of a New Class of Flexible Augmented Clinical Trial Designs

Author:

Dunger‐Baldauf Cornelia1ORCID,Hemmings Rob2,Bretz Frank13ORCID,Jones Byron4ORCID,Schiel Anja5,Holmes Chris67ORCID

Affiliation:

1. Statistical Methodology, Novartis Pharma AG Basel Switzerland

2. Consilium Salmonson & Hemmings Herts UK

3. Section for Medical Statistics, Center for Medical Statistics, Informatics, and Intelligent Systems Medical University of Vienna Vienna Austria

4. Novartis UK Camberley UK

5. Norwegian Medicines Agency Oslo Norway

6. University of Oxford Oxford UK

7. The Alan Turing Institute London UK

Abstract

To support informed decision making, clear descriptions of the beneficial and harmful effects of a treatment are needed by various stakeholders. The current paradigm is to generate evidence sequentially through different experiments. However, data generated later, perhaps through observational studies, can be difficult to compare with earlier randomized trial data, resulting in confusion in understanding and interpretation of treatment effects. Moreover, the scientific questions these later experiments can serve to answer often remain vague. We propose Flexible Augmented Clinical Trial for Improved eVidence gEneration (FACTIVE), a new class of study designs enabling flexible augmentation of confirmatory randomized controlled trials with concurrent and close‐to‐real‐world elements. Our starting point is to use clearly defined objectives for evidence generation, which are formulated through early discussion with health technology assessment (HTA) bodies and are additional to regulatory requirements for authorization of a new treatment. These enabling designs facilitate estimation of certain well‐defined treatment effects in the confirmatory part and other complementary treatment effects in a concurrent real‐world part. Each stakeholder should use the evidence that is relevant within their own decision‐making framework. High quality data are generated under one single protocol and the use of randomization ensures rigorous statistical inference and interpretation within and between the different parts of the experiment. Evidence for the decision making of HTA bodies could be available earlier than is currently the case.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference13 articles.

1. “Threshold‐crossing”: A Useful Way to Establish the Counterfactual in Clinical Trials?

2. Transforming Evidence Generation to Support Health and Health Care Decisions

3. Ray R. Locke T. Hendricks‐Sturrup R.Aligning shared evidentiary needs among payers and regulators for a real‐world data ecosystem (2022).

4. ICH.International Council for Harmonisation Topic E9(R1): Addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials (2019).

5. Target estimands for population‐adjusted indirect comparisons

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3